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Comparison of Fentanyl and Nalbuphine in Total Intravenous
Anaesthesia (TIVA)
F.A. Khan,Hameedullah ( Department of Anaesthesiology, The Aga Khan University, Karachi. )

Abstract
Objective: To compare Nalbuphine and fentanyl as total intravenous anaesthesia with propofol
infusion in laproscopic cholecystectomy cases.
Study design: Double blind randomised.
Methods: Changes in haemodynamic variables greater than twenty percent above or below the
baseline and recovery profile were observed.
Results: Blood pressure remained within 20% of baseline in either group. Nine patients in fentanyl and
fifteen in nalbuphine group required an additional bolus of propofol intraoperatively. Heart rate
response after tracheal intubation was significantly higher in the nalbuphine group (25%). No
difference was observed in the incidence of nausea and vomiting in the recovery room. Twenty-seven
percent patients in the nalbuphine group required analgesia in the recovery in comparison to 87% in the
fentanyl group. Patients in the fentanyl group required analgesia earlier (37 minutes vs. 62 minutes).
Conclusion: Fentanyl provided better intraoperative haemodynamic stability in comparison to
nalbuphine when used as the analgesic component in total intravenous anaesthesia with propofol The
recovery profile with both drugs was similar. Lesser number of patients required analgesia in the
recovery in the nalbuphine group (JPMA 52:459;2002).
Introduction
Use of total intravenous anaesthesia (TIVA) offers particular advantages in developing countries where
there may be problems with availability of compressed gases1, calibrated vaporizers and rotameters2.
Unpredictability in the availability of drugs is another problem for anaesthetists working in these
countries and requires familiarity on their part in the use of alternatives to standard drugs. Fentanyl is
generally used as the anaesthetic component in TIVA for inpatient settings because of its high
therapeutic index and its pharmacokinetics properties but it may be associated with a variable amount
of respiratory depression at conclusion of surgery3. Use of both nalbuphine and buprenorphine in TIVA
was previously reported by us as a safe alternative4, but nalbuphine has the advantage of cardiovascular
stability and rapid recovery5.
The purpose of this study was to test the hypothesis that 0.2ug.kg-1 of fentanyl and 0.2mg.kg-1 of
nalbuphine will provide comparable suppression of intraoperative haemodynamic responses and similar
recovery profile when used as narcotic analgesic component in TIVA.
Patients and Methods
The study was approved by the Human Subjects Protection committee of the hospital and informed
consent was obtained from patients. The subjects were randomised by using sealed envelopes and study
was double blind. Blindness was assured by using coded syringes prepared by anaesthetists
unconnected with the study and those taking the recordings and assessing patients postoperatively were
also blinded.
Sixty patients aged between sixteen and sixty years and of ASA status one and two undergoing

laproscopic cholycystectomy were entered in the trial, Patients taking medication likely to affect the
cardiovascular system like antihypertensive and antidysrythmic agents, beta blockers and calcium
channel blockers were excluded. Obesity with body weight more than 30% of ideal , anticipated
difficult intubation based on Mallampatti scoring were excluded and those presenting for emergency
surgery were also excluded.
Patients enrolled in the trial received 7.5 mg of oral midazolam as premedication and were randomly
divided into two groups; group 1 received an initial bolus of nalbuphine 0.2mgkg-1 and group 2
received fentanyl 2 ug.kg-1 intravenously. Both drugs were given five minutes before induction of
anaesthesia and after taking baseline readings. Anaesthetic technique was standardized. After
preoxygenation anaesthesia was induced with propofol 2 mgkg-1 over thirty seconds followed by
vecuronium 0.1 mgkg’ over fifteen seconds. An infusion of propofol was started immediately after
induction according to the following regimen: 10 mgkg-’hr1 for the first ten minutes, 8 mgkg-1hr-1 for
the next ten minutes and 6 mgkg-’hr’ for maintenance. An Imed-Gemini PC-i infusion pump was used.
Tracheal intubation was performed three minutes after vecuronium injection. Patients’ lungs were
ventilated with an air-oxygen mixture maintaining an F102 of 0.4 A nasogastric tube was inserted in all
patients after tracheal intubation and removed before reversal of neuromuscular blockade. Patients
were ventilated at an initial tidal volume of 10 mlkg-1 and a respiratory rate of 10 breaths min-1. These
parameters were than adjusted to keep the EtC02 within 35-40 mm of Hg.
Depth of anaesthesia was assessed during the intraoperative period by observing a variation of more
than 20% above or below the baseline in systolic arterial pressure or heart rate measurements.
Lacrimation and sweating during anaesthesia were also noted. If any two of the above signs were
present a supplemental bolus of propofol 10 mg was given. If the signs persisted for more than three
minutes after the bolus the rate of infusion was again increased to 8 mgkg-’hr’ for another ten minutes.
Half the preinduction dose of analgesic was repeated from a coded syringe if the criteria for light
anaesthesia persisted. Regular hourly analgesia/placebo top-ups were given in both groups from coded
syringe to keep the study blind. Group I (Nalbuphine group) patients received saline bolus whereas
fentanyl 1.0 ug.kg-1 diluted to similar volume was given in group 2 (Fentanyl group) patients. The size
of tracheal tube and the type of laryngoscope blades were standardized. The infusion of propofol was
stopped at the time of last stitch and the neuromuscular blockade was reversed with atropine 0.02
mgkg-1 and neostigmine 0.05 mgkg-1.
The ECG was monitored continuously using lead II. Noninvasive blood pressure, oxygen saturation,
F1O2 and ETCO2 were monitored using the Datex Cardiocap monitor. Blood pressure and heart rate
were noted five minutes before and two minutes after the study drug, at one minute interval after
induction for three minutes and at one minute interval after tracheal intubation for five minutes, one
and two minutes after the dosage of propofol was altered and after termination of infusion and
extubation.
At the time of reversal, response to eye opening on command and any sign of the patient being in pain
were noted. In the recovery room patients’ ability to tell name and any complaints of pain, nausea and
vomiting were noted down. Patients were discharged from the recovery room when they fulfilled the
routine discharge criteria of our unit (PAR scoring). The time of requirement of first postoperative dose
of analgesic was also noted. Postoperative interview took place the next day. Every patient was asked
regarding any recall of events inside the operating room and any specific problems experienced after
anaesthesia.
A sample size and power analysis had shown that thirty patients per group were required to
demonstrate a twenty percent difference in blood pressure or heart rate value at a 0.05 and a power of
eighty percent. Variables were analyzed using the Epi info-6 statistical package. Analysis of variance
was used to compare the mean changes in systolic, diastolic, mean blood pressure and heart rate. The
incidence of untoward effects and other qualitative data was assessed by Chi-Square analysis. A p value
of less than 0.05 was taken as significant.

Results
Demographic data
Both groups were comparable for age, weight, preinduction systolic blood pressure, heart rate and
duration of anaesthesia (Table).

There was a significant difference in the baseline diastolic and mean pressure within the groups with
the pressures in the nalbuphine group being lower.
Haemodynamic data
Figure 1 shows the mean changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP)
in relation to time. Because of significant difference in the baseline values of DBP and MAP percentage
change from baseline was also calculated rather than the absolute change. Both groups exhibited a
decrease of less than 15% after induction. The rise after tracheal intubation was not significant
compared to the baseline in either group. The blood pressure was maintained within 20% of baseline
after incision and at the time of emergence and extubation. A significant difference in SBP was
observed between the two groups at two, three and five minutes post intubation, after decreasing
propofol infusion to maintenance levels and at the time of incision when higher levels were observed in
the nalbuphine group (Figure 1).

The changes in DBP are shown in Figure 2. DBP fell after induction. After tracheal intubation it rose to
a maximum of 13% in the nalbuphine group versus 3% in fentanyl. The pressures remained within 20%
of the baseline in all the observed readings. A significant difference was observed between the two
groups after all the readings taken after tracheal intubation except one taken two minutes after end of
surgery (Figure 2).

The mean arterial pressure mirrored the changes in DBP. These are shown in Figure 3.

Figure 4 shows the changes in heart rate. The maximum positive or negative change observed during
the study period in the fentanyl group was 6.4%. The heart rate in the nalbuphine group showed a much
higher positive variation compared to the fentanyl group. In this group the maximum response seen
after tracheal intubation was a 25% change one minute after intubation. The heart rate remained
significantly high (15%) at five minutes post intubation. In the nalbuphine group there was significant
increase compared to the baseline after incision (16%) but this was within 20% acceptable variation.
Extubation was again associated with a +15% increase in the heart rate in the nalbuphine group
compared to +4% in the fentanyl group (Figure 4).
Nine patients in the fentanyl (30%) and fifteen in the nalbuphine group (50%) required one additional
bolus of 10 mg of propofol. This difference was significant (p<0.01). None of the patients required an
increase in the rate of propofol infusion or additional nalbuphine. No untoward intraoperative effects
were observed in either group.
One patient in the fentanyl (3%) and three in the Nalbuphine group (10%) complained of nausea and
only one in fentanyl (3%) group complained of vomiting in the recovery room. No significant
difference was observed between the groups. None of the patients were excessively sedated.
First analgesic dose in the postoperative period was given on patient demand. Twenty six patients in the
fentanyl (87%) and eight in the nalbuphine (27%) group needed postoperative analgesia in the recovery
room pressure, MAP; heart rate, HR. (p<0,001). The mean time to the first analgesic dose after
extubation was 37 ± 11 minutes and 62 ± 35 minutes in fentanyl and nalbuphine groups respectively in
patients who received additional analgesia. This difference was significant (p value <0.01). The mean

time from extubation to eye opening was 4.2 ± 0.4 minutes in fentanyl and 5.2 ±0.6 minutes in the
nalbuphine group. This difference was non-significant. The mean time from extubation to the patients’
ability to tell their name was 14.2 ±. 2.6 minutes in fentanyl and 21.8 ±, 4.8 minutes in the nalbuphine
group (p<0.05). Mean discharge time from recovery room was 90 ±, 22 minutes in the fentanyl group
and 99.9 ±27 minutes in the nalbuphine group. None of the patients answered in affirmative to the three
specific questions asked in the postoperative interview.
Discussion
Several drugs could be used to achieve total intravenous anaesthesia. Propofol allows rapid changes in
the anaesthetic depth, lack of cumulation and rapid clearheaded awakening6 and is a logical choice.
Speed of awakening was shown to be unaffected by infusion given for 24, 48, 72 and 96 hours7,
Addition of a narcotic agent to propofol is required, as propofol has no analgesic properties; this also
reduces the dose of intravenous anaesthetic thus resulting in lesser side effects. Ideally the narcotic
should be with a short half-life allowing rapid changes in anaesthetic depth and quick recovery.
Fentanyl8, alfentanil9, sufentaniP10 and remifentanil11,12 have all been used or recommended for
analgesia during TIVA.
Resource variability is a major problem in developing countries and working conditions may vary from
excellent to poor. One of the challenges of working in these places is the non-availability or sudden
shortages of newer short acting drugs forcing anaesthetists to look for safe alternatives. Longer acting
narcotics, like pethidine antagonist or partial agonist drugs offer a degree of safety in and morphine,
have been used in TIVA13, Agonist above mentioned circumstances because of the ceiling effect on
respiration, and are especially beneficial in situation where recovery facilities are lacking. Both
buprenorphine and nalbuphine have been used in TIVA4, 14 and found to be safe alternatives. However,
effect of these drugs has not been directly compared with fentanyl.
Nalbuphine is chemically related to naloxone. It has a ceiling effect for respiratory depression and is
said to cause less nausea and vomiting compared to morphine, pethidine or pentazocine15.
Our dosage selection of the two drugs is open to critique however equipotent doses of these drugs have
not been fully established. The ED50 of nalbuphine in rats was found to be 1.2 mg.kg1 compared to
0.98 mg.kg-’ for morphine indicating its potency to be 0.7-0.8 times that of morphine16. Higher dose
requirements have been reported for use in balanced anaesthesia in humans where dose has ranged
from 0.15-2 mg.kg-117. We selected the dosages in our study based on the assumption that nalbuphine
is equipotent to morphine18. Fentanyl on an mg basis is about 80 times more potent than morphine19
and a dose of 2 was therefore chosen to be equipotent to nalbuphine 0.2 mg.kg-1. The background
Propofol regimen used was Robert’s regimen with a slight alteration of a 2 mgkg-120induction dose
instead of 1 mgkg-120. This manual scheme was designed to achieve a blood propofol concentration of
3-4 ug.kg-1 within five minutes and then maintain it at constant level21. The use of manual regiments is
now replaced by Target Controlled Infusion (TCI) pumps in developed countries22 but again these are
not generally available in the developing world.
A difference was observed in the blood pressure response between the two drugs. The response after
tracheal intubajtion and incision was higher in the nalbuphine group. A significant difference was also
observed in heart rate response with the response being significantly lower in the fentanyl group after
induction, tracheal intubation and incision.
Thirty percent patients in the fentanyl compared to 50% patients in the nalbuphine group required
supplemental propofol bolus. Both narcotic and propofol bolus have been found to be equally effective
in controlling haemodynamic and hormonal response to surgical stimuli during TIVA23. All patients in

the fentanyl group received additional analgesia one hour following the induction dose. This was done
in a blind manner. It was considered unethical not to provide additional analgesia in the fentanyl group
because of its shorter half life. This additional bolus dose because of its timing could not have affected
the blood pressure and heart rate readings till after the incision. It is possible that inadequate effect of
nalbuphine 0.2 mgkg-1 may be due to insufficient dosage and further depression of the response is
possible by increasing the dose further although one of the disadvantages suggested for this drug is that
larger doses may contribute little to the analgesic effect but increases sedation24. Fentanyl 2 mg.kg-1
given at induction therefore provided better analgesia.
The recovery profile was the same for both groups except for the patients’ ability to tell their name,
which was earlier in the fentanyl group. The incidence of postoperative nausea and vomiting seen in the
recovery room was very low. The reported incidence of ppstoperative nausea and vomiting in
laproscopic cholecystectomy is high with approximately 50% of the patients requiring antiemetics25,
This low incidence was also seen in our previous study.
One of the reasons could be the routine insertion of nasogastric tube intraoperatively which was
removed at the end of the procedure. Use of TIVA may also account for minimizing emesis by
eliminating the effect of N 20 on bowel distension. An added advantage seen in the nalbuphine group
was that lesser number of patients needed analgesia in the recovery room and hence the need for lesser
monitoring.
Awareness was not reported in any of our patients. The reported incidence of awareness in TIVA is
comparable to that of standard balanced anaesthesia techniques using muscle relaxants26.
In conclusion, nalbuphine group provided lesser haemodynamic stability in comparison to fentanyl
when used as an intraoperative analgesic in TIVA with propofol. The recovery profile was similar.
Nalbuphine group required lesser postoperative analgesia in the recovery room.
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